We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Oral Mucosal Absorption of ICI176,334-1

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01415791
First Posted: August 12, 2011
Last Update Posted: May 30, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
AstraZeneca
  Purpose
The purpose of this study is to investigate the presence or absence of oral mucosal absorption of ICI176,334-1

Condition Intervention Phase
Healthy Drug: ICI176,334-1 Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Oral Mucosal Absorption of ICI176,334-1 in Japanese Healthy Male Subjects

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • To investigate the presence or absence of oral mucosal absorption of ICI176,334-1 by assessment of concentration of bicalutamide in plasma [ Time Frame: Samples are taken at 72 hours after application of the investigational drug ]
  • To investigate the presence or absence of oral mucosal absorption of ICI176,334-1 by assessment of concentration of bicalutamide in plasma [ Time Frame: Samples are taken at 168 hours after application of the investigational drug ]
  • To investigate the presence or absence of oral mucosal absorption of ICI176,334-1 by assessment of concentration of bicalutamide in saliva [ Time Frame: Samples are taken at 72 hours after application of the investigational drug ]
  • To investigate the presence or absence of oral mucosal absorption of ICI176,334-1 by assessment of concentration of bicalutamide in saliva [ Time Frame: Samples are taken at 168 hours after application of the investigational drug ]

Secondary Outcome Measures:
  • To assess the safety by assessment of adverse event [ Time Frame: Adverse Events will be captured starting from screening up to 14 to 21 days (follow-up) ]
  • To evaluate the safety by evaluation of vital signs [ Time Frame: Collect prior to treatment and up to 14 to 21 days (follow-up) after application of the investigational drug ]
  • To evaluate the safety by assessment of electrocardiograms (ECGs) [ Time Frame: Collect prior to treatment and up to 14 to 21 days (follow-up) after application of the investigational drug ]

Enrollment: 8
Study Start Date: August 2011
Study Completion Date: September 2011
Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Active 1
8 subjects will receive ICI176,334-1
Drug: ICI176,334-1
Subject will receive single dose of ICI176,334-1

Detailed Description:
Oral mucosal absorption of ICI176,334-1 in Japanese healthy male subjects
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Provision of signed and dated, written informed consent prior to any study specific procedures
  • Japanese healthy male subjects aged 20 to 45 years
  • Male subjects should be willing to use barrier contraception ie, condoms, until 3 months after the last dose of investigational product
  • Have a body mass index (BMI) between 17 and 27 kg/m2
  • Eligible based on the physical findings, supine BP, pulse rate, ECG and laboratory assessments, as judged by the investigator(s)

Exclusion Criteria:

  • Presence of any disease under medical treatment
  • History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, immunological, blood, endocrine, neurological or mental disease to interfere with absorption, distribution, metabolism or excretion of drugs judged by investigator(s)
  • Presence of any infectious disease, such as bacteria, virus and fungus Presence of allergic disorder, such as asthma, pollen disease or atopic dermatitis, and judged as necessary any medical treatment
  • Any large surgical history of gastrointestinal tract such as gastric/intestinal resection or suturation
  Contacts and Locations
No Contacts or Locations Provided
  More Information

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT01415791     History of Changes
Other Study ID Numbers: D6874L00026
First Submitted: August 11, 2011
First Posted: August 12, 2011
Last Update Posted: May 30, 2012
Last Verified: May 2012

Keywords provided by AstraZeneca:
oral mucosal absorption
pharmacokinetics
safety
bicalutamide
Japanese
healthy subject

Additional relevant MeSH terms:
Bicalutamide
Androgen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents